SecBot SecBot
S-3 ·Filed Apr 22, 2026

VREOF

Vireo Growth Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001104659-26-047026
Shelf registration, potential dilution
Actionable Insight • Neutral

Monitor for actual sales by the listed securityholders, as significant volume could pressure the stock price. The recent acquisition of Hawthorne adds scale but also brings integration risks and potential dilution of up to 19% from warrants.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$13.50
T+0 close · Apr 23, 2026 · via day close
Latest settled
−27.41%
T+60 · $9.80
Vs SPY
−32.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 23 $13.50entry
  2. T+1 · 7mo ago 0.00%α −0.77% · $13.50
  3. T+5 · 7mo ago −2.22%α −3.66% · $13.20
  4. T+20 · 6mo ago −6.89%α −11.73% · $12.57
  5. T+60 · 4mo ago −27.41%α −32.43% · $9.80

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vireo Growth Inc. has filed a shelf registration (S-3) to allow the resale of 3,097,390 subordinate voting shares held by selling securityholders, originally issued as consideration in a note purchase agreement related to the Schwazze transaction. The company will not receive proceeds from these sales, which are expected to occur from time to time. This follows recent significant M&A activity including the Hawthorne acquisition.

Key Financial Metrics

Offering Size
$1.4M

Key Facts

  • S-3 shelf registration filed for resale of 3,097,390 subordinate voting shares by selling securityholders
  • Shares were issued at $0.54 per share as consideration in a note purchase agreement with Schwazze noteholders
  • Company will not receive any proceeds from the resale of these shares
  • Recent M&A activity includes the $110M cash and net working capital acquisition of The Hawthorne Gardening Company
  • Shares are registered for resale, not for new issuance by the company

Financial Impact

No financial impact to company as it will not receive proceeds from the resale of 3,097,390 shares

dilution

Risk Factors

  • Sales of substantial amounts of shares by securityholders could adversely affect the market price
  • The company's recent acquisition activity and debt financing create integration and financial risks

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
S-3 Filing (Primary)0001104659-26-047026
Document: tm2612405d1_ex-filingfees.htm0001104659-26-047026
Document: tm2612405d1_ex5-1.htm0001104659-26-047026
Document: tm2612405d1_ex23-1.htm0001104659-26-047026
Document: 0001104659-26-047026-index-headers.html0001104659-26-047026
Document: 0001104659-26-047026-index.html0001104659-26-047026
Document: 0001104659-26-047026.txt0001104659-26-047026

US Market Status

Market Closed · Opens in 6h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026